Search
Motexafin gadolinium
go.drugbank.com/drugs/DB05428InvestigationalMotexafin gadolinium is studied in the treatment of cancer by Pharmacyclics. It may make tumor cells more sensitive to radiation therapy, improve tumor images using magnetic resonance imaging (MRI), and kill cancer cells. It belongs to t...
Categories: Compounds used in a research, industrial, or household settingDAS-431 IV
go.drugbank.com/drugs/DB05432ExperimentalDAS-431 IV is a dopamine D1 receptor agonist developed by DrugAbuse Sciences for the treatment of Addictions, Schizophrenia, Schizoaffective Disorders, Dementia, Parkinson's Disease, Strokes etc.
rGLP-1
go.drugbank.com/drugs/DB05433ExperimentalGLP-1 is a naturally occurring hormone produced in the intestines in response to food intake. … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant.
FM-VP4
go.drugbank.com/drugs/DB05449InvestigationalFM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.
PH-284
go.drugbank.com/drugs/DB05452ExperimentalPH-284 belongs to a new family of new chemical entities called vomeropherins. … Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages.
ETC-588
go.drugbank.com/drugs/DB05456ExperimentalEsperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes.
Pozanicline
go.drugbank.com/drugs/DB05458InvestigationalABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalAt low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, an...
Tandutinib
go.drugbank.com/drugs/DB05465InvestigationalMLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT. … Approximately 25 to 30 percent of all adult AML patients have a mutation of the FLT3 gene. The use of MLN518 to treat AML has been granted fast-track status by the U.S. Food and Drug Administration.
R673
go.drugbank.com/drugs/DB05466ExperimentalR673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential.